RO7871996 first-in-human dose-escalation and dose-finding study in active systemic lupus erythematosus

Phase 2, open-label trial of RO7871996 in systemic lupus erythematosus (SLE) (2 arms), sponsored by Roche. Primary endpoints: Nature and incidence of dose-limiting adverse events, Nature, frequency, seriousness, relatedness and severity of adverse events and 2 more. Planned start Oct 2026; status: authorised.